Volume 1, Issue 8
Editorialp. 1061
Randomized dose-finding studies: how many dose levels should be used?
Author(s): Yinghui Zhou
Editorialp. 1065
Inclusion of patients with brain metastases in clinical trials
Author(s): Lauren E Abrey
Review Articlep. 1083
Considerations in the design of clinical trials of antibacterial agents for ventilator-associated pneumonia
Author(s): John Muscedere
Therapeutic Prospectivep. 1095
New advances in the treatment of Friedreich ataxia: promises and pitfalls
Author(s): Wolfgang Nachbauer, Sylvia Boesch
Review Articlep. 1107
Triple-negative breast cancer and new treatment developments
Author(s): Stephen Dyar, Alvaro Moreno-Aspitia
Review Articlep. 1119
The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence
Author(s): Andrew J Weickhardt, D Ross Camidge
Review Articlep. 1127
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
Author(s): Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu
Review Articlep. 1155
The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes
Author(s): Beau M Hawkins, Jorge F Saucedo, Sunil V Rao
Review Articlep. 1141
Impact of recent landmark clinical trials on hypertension treatment
Author(s): Ikechi G Okpechi, Brian L Rayner
Review Articlep. 1167
Medical therapy for renal artery stenosis
Author(s): William R Colyer Jr, Christopher J Cooper
Review Articlep. 1175
y-secretase inhibitors for treating Alzheimer\\\'s disease: rationale and clinical data
Author(s): Francesco Panza, Vincenza Frisardi, Bruno P Imbimbo, Davide Seripa, Vincenzo Solfrizzi, Alberto Pilotto
Editor\\\'s Notep. 1198
